Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

Dr Reddy's share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to 'Buy' with a target of ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. If side effects from Revlimid become difficult to ...

Tecvayli, alone or with Revlimid, showed robust efficacy in newly diagnosed multiple myeloma post-ASCT, achieving 100% MRD-negativity in all cohorts. Complete remission rates were highest in cohort 1, ...

The U.S. Food and Drug Administration has approved the anemia drug Revlimid (lenalidomide) as a treatment for multiple myeloma, which is a type of blood cancer. The U.S. Food and Drug ...